SB1938 would create the “Oklahoma DNA/RNA-Based Vaccine Safety and Sovereignty Act” and prohibit the use, sale, distribution, manufacture, administration, or facilitation of DNA/RNA-based vaccines and related products in Oklahoma. The bill defines these products broadly to include mRNA, modRNA, saRNA, DNA-based vaccines, certain gene therapy products, genetically modified microorganisms, genome-editing tools, and ex vivo genetically modified human cells. It applies to human, animal, and agricultural uses and expressly states that the prohibition would apply even during declared emergencies.
The bill also establishes enforcement and penalty provisions. Violations would trigger civil and criminal penalties, including a minimum $50,000 fine per violation, with each distribution or administration to a separate person, animal, or agricultural product counted separately. Knowingly and willfully violating the act would be a felony punishable by up to a $250,000 fine, up to 10 years in prison, or both. The Attorney General would be authorized to investigate, prosecute, and seek injunctions and restitution, while private residents exposed in violation of the act could sue for compensatory and punitive damages, attorney fees, and costs. Whistleblowers would receive retaliation protections and could be eligible for a reward of up to 30% of collected fines.
If enacted, the bill would add a new uncodified act and a new section to Title 63 of the Oklahoma Statutes, creating a statewide ban on a broad category of genetic and nucleic-acid-based vaccine technologies. It would significantly affect vaccine manufacturers, distributors, healthcare providers, veterinarians, agricultural entities, and state agencies by restricting products that are currently used or regulated in public health, animal health, and biotechnology contexts. The bill’s effective date is November 1, 2026.
The available context shows little formal legislative debate or recorded voting activity, so sentiment must be inferred primarily from the bill’s framing. The bill is written in strongly supportive terms toward prohibition, emphasizing health, safety, autonomy, informed consent, and scientific integrity, and it reflects a clear anti-DNA/RNA-vaccine policy position. The only recorded action in the provided context is that it was coauthored by Senator Prieto, but no committee transcripts or votes are available to show broader legislative support or opposition.
The main points of contention are likely to be the bill’s sweeping scope, its inclusion of mRNA and gene therapy-related technologies, and its application to humans, animals, and agriculture. Critics would likely argue that the bill conflicts with existing medical and public health regulation, could interfere with emergency response tools, and may be difficult to reconcile with federal oversight of vaccines and biologics. Supporters would likely view it as a precautionary measure to prevent use of what the bill describes as untested or potentially hazardous technologies.
The bill would create a new, broad prohibition on DNA/RNA-based vaccines and related genetic technologies in Oklahoma, with criminal and civil penalties and private enforcement rights. It would affect state law by adding a new uncodified act and a new section to Title 63, while also authorizing Attorney General enforcement, whistleblower rewards, and civil lawsuits by affected residents. The practical impact would extend to healthcare, veterinary, agricultural, and biotechnology sectors by barring manufacture, sale, distribution, administration, or facilitation of these products in the state.
The bill’s text reflects strong support for restricting DNA/RNA-based vaccines, using language centered on safety, sovereignty, informed consent, and protection from perceived risks. Because no committee transcripts or votes are provided, there is no documented floor or committee sentiment to measure, but the bill’s introduction and framing suggest it is driven by a skeptical or oppositional view of mRNA and related technologies. The recorded coauthorship indicates at least some legislative backing, though the broader level of support or opposition is not shown in the available materials.
Likely contention centers on the bill’s very broad definition of DNA/RNA-based vaccines, which reaches beyond conventional vaccines to include gene therapy products, genome-editing tools, genetically modified microorganisms, and ex vivo modified cells. Opponents would likely object to the statewide ban applying to humans, animals, and agriculture, as well as the severe penalties, private right of action, and whistleblower bounty provisions. Supporters would likely argue the bill is necessary to prevent use of technologies they view as risky or insufficiently tested, especially during emergencies.